Older adults and those with metabolic conditions such as obesity also received significant benefits against stroke and death.

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving Long COVID symptoms, according to a new study published in The Lancet Infectious Diseases on April 3. “This is ...

Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission.

The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers "compounds and pharmaceutically acceptable ...

CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered to ...

CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and the COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered ...

they have 1 or more risk factors for progression to severe COVID‑19 (as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for ...

It is a possible treatment for mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, if: they have any risk factors that make it more likely to develop severe COVID-19 and both ...